Beautiful Virgin Islands

Saturday, Oct 25, 2025

Even more evidence shows vaccinated people are unlikely to transmit the coronavirus or get asymptomatic infections

Even more evidence shows vaccinated people are unlikely to transmit the coronavirus or get asymptomatic infections

A new study shows that Pfizer's shot prevents asymptomatic infections almost as well as symptomatic cases of COVID-19.

Once effective coronavirus vaccines were authorized and started getting distributed, the crucial question became: Do they stop transmission?

In clinical trials, Pfizer and Moderna showed that their shots prevent symptomatic COVID-19, but they didn't test whether their vaccines prevent asymptomatic cases. Without curtailing symptom-less infections, it's difficult to stop transmission from person to person. But a growing body of evidence suggests that people who get these vaccines don't spread the virus after all.

Pfizer announced Thursday that its vaccine appears to be 94% effective at preventing asymptomatic infections two weeks after people receive their second dose. The study compared unvaccinated people in Israel to those who got the Pfizer shot between January 17 and March 6.

The findings are "particularly meaningful as we look to disrupt the spread of the virus around the globe," Dr. Luis Jodar, Pfizer's chief medical officer, said in a press release.

Vaccinated people may be less contagious if they get infected
People on the London Underground on September 25, 2020.

Research shows the more viral particles a person has in their mouth and nose — what's known as viral load — the more likely they are to pass the coronavirus to others. Reduced viral loads are linked to lower transmission rates.

So a vaccine should reduce transmission if it can ensure that even those who still get the coronavirus after their shots, whether a symptomatic or asymptomatic case, have a lower viral load than they would otherwise.

A February study from Israel, which has yet to be peer-reviewed, found that starting 12 days after vaccination, the people who got COVID-19 despite getting Pfizer's shots had four times less virus in their bodies.

The researchers looked at more than 1,000 people who'd tested positive for the virus after being fully vaccinated in Tel Aviv. Those people's viral loads in the period from 12 to 28 days after their second dose were four times lower than their viral loads in the first 11 days after vaccination.

Another study from Israel, also not yet peer-reviewed, suggested the Pfizer vaccine reduced viral loads by a factor of up to 20.

Some research suggests viral loads are linked to disease severity, so a patient with a lower viral load is also less likely to have severe COVID-19. That may in part explain why Pfizer's vaccine significantly reduces the chance of symptomatic infection.

Vaccinated people are less likely to develop asymptomatic infections
Dr. Jason Smith shows off his bandage after getting vaccinated at the University of Louisville Hospital in Kentucky.


To pinpoint whether vaccines truly reduce spread, it's critical to determine whether the shots prevent asymptomatic COVID-19 cases in addition to symptomatic infections.

Pfizer and Moderna's clinical trials only tested volunteers for COVID-19 if they felt ill. Otherwise, the companies would have had to require regular COVID-19 testing for all tens of thousands of volunteers. So at first, neither company could say whether their vaccines prevent asymptomatic cases.

But Moderna did test trial volunteers on the day they got their second shots. And the findings suggested that there were fewer asymptomatic infections among participants who'd received the real vaccine than among those who got a placebo. Just 14 people of the 14,000-plus in the trial's vaccine group had asymptomatic cases that day, compared to 38 of the similarly sized placebo group.

That's a 61.5% drop, according to Marm Kilpatrick, a disease ecologist at the University of California, Santa Cruz. He wrote on Twitter last month that the data suggests Moderna's vaccine blocks about 91% of transmission.

A man receives a COVID-19 vaccine at a health services center in Rehovot, Israel, on January 14, 2021.


Animal studies offer similar findings: An October paper found that the Moderna vaccine prevented the coronavirus from replicating in the nose, throat, and lungs of rhesus macaques four weeks after they'd been vaccinated. If the viral particles can't copy themselves, it's unlikely an infected host will pass on particles to others.

Before the Pfizer findings announced Thursday, a preliminary study published in The Lancet found the shot to be at least 85% effective at preventing any type of infection — symptomatic or asymptomatic. That study looked at more than 23,000 healthcare workers across hospitals in the UK.

Additionally, a recent study found that people who'd received at least one dose of a mRNA vaccine — from either Pfizer or Moderna — were 72% less likely to test positive for an asymptomatic infection 10 days after their shot, relative to unvaccinated people. The research looked at more than 39,000 Americans.

Johnson & Johnson's trial data on asymptomatic infections also seems promising. The company tested blood samples from almost 3,000 participants for coronavirus antibodies 71 days after they'd been vaccinated. (The presence of antibodies suggests participants had been infected even if they didn't show symptoms.) Only two vaccinated people tested positive, whereas 16 people who'd received a placebo did, according to data released last month from the Food and Drug Administration.

That suggests J&J's vaccine may be 74% effective against asymptomatic infections, though the FDA noted that more data is needed to be sure.

Vials of the Pfizer-BioNTech COVID-19 vaccines at Renown Health in Reno, Nevada on December 17, 2020.


Even the Oxford-AstraZeneca vaccine, which is still in clinical trials in the US, may reduce asymptomatic infections.

A February Oxford study, which has yet to be peer reviewed, found that among people who received just one dose, the number of positive COVID-19 tests — among both symptomatic and asymptomatic study participants — fell by 67%.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Microsoft AI CEO: ‘We’re making an AI that you can trust your kids to use’ — but can Microsoft rebuild its own trust before fixing the industry’s?
China and Russia Deploy Seductive Espionage Networks to Infiltrate U.S. Tech Sector
Apple’s ‘iPhone Air’ Collapses After One Month — Another Major Misstep for the Tech Giant
Graham Potter Begins New Chapter as Sweden Head Coach on Short-Term Deal
Ecuadorian President Daniel Noboa Alleges Poison Plot via Chocolate and Jam
Lakestar to Halt External Fundraising as Investor in Revolut and Spotify
U.S. Innovation Ranking Under Scrutiny as China Leads Output Outputs but Ranks 10th
Three Men Arrested in London on Suspicion of Spying for Russia
Porsche Reverses EV Strategy as New CEO Bets on Petrol and Hybrids
Singapore’s Prime Minister Warns of ‘Messy’ Transition to Post-American Global Order
Andreessen Horowitz Sets Sights on Ten-Billion-Dollar Fund for Tech Surge
US Administration Under President Donald Trump Reportedly Lifts Ban on Ukraine’s Use of Storm Shadow Missiles Against Russia
‘Frightening’ First Night in Prison for Sarkozy: Inmates Riot and Shout ‘Little Nicolas’
White House Announces No Imminent Summit Between Trump and Putin
US and Qatar Warn EU of Trade and Energy Risks from Tough Climate Regulation
Apple Challenges EU Digital Markets Act Crackdown in Landmark Court Battle
Nicolas Sarkozy begins five-year prison term at La Santé in Paris
Japan stocks surge to record as Sanae Takaichi becomes Prime Minister
This Is How the 'Heist of the Century' Was Carried Out at the Louvre in Seven Minutes: France Humiliated as Crown with 2,000 Diamonds Vanishes
China Warns UK of ‘Consequences’ After Delay to London Embassy Approval
France’s Wealthy Shift Billions to Luxembourg and Switzerland Amid Tax and Political Turmoil
"Sniper Position": Observation Post Targeting 'Air Force One' Found Before Trump’s Arrival in Florida
Shouting Match at the White House: 'Trump Cursed, Threw Maps, and Told Zelensky – "Putin Will Destroy You"'
Windows’ Own ‘Siri’ Has Arrived: You Can Now Talk to Your Computer
Thailand and Singapore Investigate Cambodian-Based Prince Group as U.S. and U.K. Sanctions Unfold
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
Chinese Tech Giants Halt Stablecoin Launches After Beijing’s Regulatory Intervention
Manhattan Jury Holds BNP Paribas Liable for Enabling Sudanese Government Abuses
Trump Orders Immediate Release of Former Congressman George Santos After Commuting Prison Sentence
S&P Downgrades France’s Credit Rating, Citing Soaring Debt and Political Instability
Ofcom Rules BBC’s Gaza Documentary ‘Materially Misleading’ Over Narrator’s Hamas Ties
Diane Keaton’s Cause of Death Revealed as Pneumonia, Family Confirms
Former Lostprophets Frontman Ian Watkins Stabbed to Death in British Prison
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
Outsider, Heroine, Trailblazer: Diane Keaton Was Always a Little Strange — and Forever One of a Kind
Dramatic Development in the Death of 'Mango' Founder: Billionaire's Son Suspected of Murder
Two Years of Darkness: The Harrowing Testimonies of Israeli Hostages Emerging From Gaza Captivity
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
HSBC Confronts Strategic Crossroads as NAB Seeks Only Retail Arm in Australia Exit
U.S. Chamber Sues Trump Over $100,000 H-1B Visa Fee
Shenzhen Expo Spotlights China’s Quantum Step in Semiconductor Self-Reliance
China Accelerates to the Forefront in Global Nuclear Fusion Race
Yachts, Private Jets, and a Picasso Painting: Exposed as 'One of the Largest Frauds in History'
Australia’s Wedgetail Spies Aid NATO Response as Russian MiGs Breach Estonian Airspace
McGowan Urges Chalmers to Cut Spending Over Tax Hike to Close $20 Billion Budget Gap
Victoria Orders Review of Transgender Prison Placement Amid Safety Concerns for Female Inmates
U.S. Treasury Mobilises New $20 Billion Debt Facility to Stabilise Argentina
French Business Leaders Decry Budget as Macron’s Pro-Enterprise Promise Undermined
Trump Claims Modi Pledged India Would End Russian Oil Imports Amid U.S. Tariff Pressure
×